Unimark Remedies Ltd (Shamrock Group)

We are a USFDA and EUGMP approved facility manufacturing APIs with 25 DMFs, 12 CEPs. Our key products are Tigecycline, Lisinopril, Montelukast, Nitrofurantoin, Nalidixic Acid, Flecainide, Moxifloxacin and Carbapenems. Our facilities have been certified by the US FDA, MHRA, EDQM, COFEPRIS,TGA, WHO and other MOH. The management of the company has changed recently, the Shamrock Pharma Group now has 100% ownership.   We have upgraded the facilities to improve quality standards, making it a world class API facility with a combined capacity of 350 KL.